Engrail Initiates ENX-104 Program For Depression
18 Sep 2024 //
GLOBENEWSWIRE
Engrail Therapeutics Appoints New CFO And Board Member
08 Aug 2024 //
GLOBENEWSWIRE
Engrail Raises $157M in Oversubscribed Series B to Move Neuro Pipeline Forward
20 Mar 2024 //
BIOSPACE
Engrail Closes Oversubscribed $157M Series B Financing
19 Mar 2024 //
BUSINESSWIRE
Engrail Therapeutics Initiates the ENCALM Phase 2 Clinical Trial of ENX-102
18 Jul 2023 //
BUSINESSWIRE
Engrail Therapeutics Announces Positive Results of ENX-101 PIb Study
07 Jun 2022 //
BUSINESSWIRE
Engrail and The Texas A&M University System Enter Licensing Agreement
08 Sep 2021 //
BUSINESSWIRE
Engrail Therapeutics Extends Series A Financing to $64 Million
04 Aug 2021 //
BUSINESSWIRE
Engrail Therapeutics Acquires NeuroCycle Therapeutics
02 Feb 2021 //
BIOSPACE